Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.
作者： Akihiro Yoshimoto , Kanako Inuzuka , Toshiyuki Kita , Atsuhiro Kawashima , Kazuo Kasahara
DOI: 10.1097/MAJ.0B013E31803B8ACB
关键词: Gefitinib 、 Lung 、 Medicine 、 Refractory 、 Epidermal growth factor receptor 、 Chemotherapy 、 Cancer research 、 Respiratory disease 、 EGFR Gene Amplification 、 Lung cancer
摘要: Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor, and it shows favorable antitumor activity against chemorefractory nonsmall cell lung cancer (NSCLC). However, patients with NSCLC have few treatment options available if they are refractory to gefitinib. We describe a 49-year-old patient who had complete response initial gefitinib that lasted for 12 months. The tumor relapsed, the received cytotoxic chemotherapy. despite chemotherapy, radiographic progression of metastases we commenced retreatment gefitinib, showing remarkable effect. Epidermal (EGFR) gene analysis showed deletion mutations in codon 745-750 exon 19 EGFR amplification. Our case after may show administration certain time has elapsed since previous treatment.
sci-hub.se 参考文章(20)
Seiji Yano,, Emiko Nakataki, Shinsaku Ohtsuka, Mami Inayama, Hideki Tomimoto, Nobutaka Edakuni, Soji Kakiuchi, Naoki Nishikubo, Hiroaki Muguruma, Saburo Sone, Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncology Research. ,vol. 15, pp. 107- 111 ,(2005) , 10.3727/096504005775082020
Adi F. Gazdar, Shinichi Toyooka, Kazunori Tsukuda, Mitsune Tanimoto, Masahiro Tabata, Kouichi Ichimura, Masaaki Yano, Toshihide Tsuda, Hisayuki Shigematsu, Hiroshi Date, Kunitoshi Tomii, Nobuyoshi Shimizu, Hiroshi Ueoka, Motoi Aoe, Masaki Tokumo, Katsuyuki Kiura, The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers Clinical Cancer Research. ,vol. 11, pp. 1167- 1173 ,(2005)
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi, Stefania Bartolini, Giovanni L. Ceresoli, Lynne Bemis, Jerry Haney, Samir Witta, Kathleen Danenberg, Irene Domenichini, Vienna Ludovini, Elisabetta Magrini, Vanesa Gregorc, Claudio Doglioni, Angelo Sidoni, Maurizio Tonato, Wilbur A. Franklin, Lucio Crino, Paul A. Bunn, Marileila Varella-Garcia, Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 97, pp. 643- 655 ,(2005) , 10.1093/JNCI/DJI112
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
Katsuyuki Hotta, Katsuyuki Kiura, Masahiro Tabata, Shingo Harita, Kenichi Gemba, Toshiro Yonei, Akihiro Bessho, Tadashi Maeda, Tomonori Moritaka, Takuo Shibayama, Keisuke Matsuo, Katsuya Kato, Arihiko Kanehiro, Yasushi Tanimoto, Keitaro Matsuo, Hiroshi Ueoka, Mitsune Tanimoto, Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer Journal. ,vol. 11, pp. 417- 424 ,(2005) , 10.1097/00130404-200509000-00010
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh, Yoshitsugu Horio, Toyoaki Hida, Shoichi Mori, Shunzo Hatooka, Masayuki Shinoda, Takashi Takahashi, Yasushi Yatabe, Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence Journal of Clinical Oncology. ,vol. 23, pp. 2513- 2520 ,(2005) , 10.1200/JCO.2005.00.992
Ross A. Okimoto, Brian W. Brannigan, Dennis C. Sgroi, Beth Muir, Markus J. Riemenschneider, Renee Bailey Iacona, Annetta D. Krebs, David H. Johnson, Giuseppe Giaccone, Roy S. Herbst, Christian Manegold, Masahiro Fukuoka, Mark G. Kris, José Baselga, Judith S. Ochs, Daniel A. Haber, Daphne W. Bell, Thomas J. Lynch, Sara M. Haserlat, Patricia L. Harris, Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials Journal of Clinical Oncology. ,vol. 23, pp. 8081- 8092 ,(2005) , 10.1200/JCO.2005.02.7078
Teh-Ying Chou, Chao-Hua Chiu, Ling-Hui Li, Chun-Yen Hsiao, Chin-Yuan Tzen, Kuo-Ting Chang, Yuh-Min Chen, Reury-Perng Perng, Shih-Feng Tsai, Chun-Ming Tsai, Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 11, pp. 3750- 3757 ,(2005) , 10.1158/1078-0432.CCR-04-1981